






Persistent breast pain (PBP) after breast cancer surgical treatment has been reported in up to half of all breast cancer survivors, a relatively higher prevalence compared to other forms of surgery. 
This particular topic holds public health significance because the development of PBP is a complex multifactorial process that can have profound negative effects. Multiple studies have found that the development of PBP can lead to decreases functionality, increased psychological distress (including worry and anxiety), and reduces the quality of life. Breast cancer is the most fatal gynecological malignancy. In the last decade, the incidence of breast cancer has increased which can be attributed to an aging population, earlier and improved methods of detection, and population growth. As the incidence rate and morbidity have increased so has the incidence of breast cancer survivors. With increase breast survivorship comes the burden of survivors dealing with complications and sequalae decreasing their quality of life. Other complications such as lymphedema, neuropathy/pain and fatigue have been well defined. The same cannot be said about persistent breast pain which has been poorly described in the literature. 
	The present study was conducted to explore the possible contribution of various demographic and clinical variables peri-operatively to the development of PBP.	The results of the study revealed statistically significant relationships between the development of PBP following surgery and the following clinical variables: undergoing a sentinel lymph node biopsy, post-operative lymphedema and surgical complications. In addition, the timing of the self-reported assessment of pain relative to surgery (months since surgery) was also found to be predictive of PBP post-surgery. Interestingly, participants reporting PBP that began in the months preceding breast cancer surgery were found to be significantly more likely to have received neoadjuvant chemotherapy during that time. 
	These findings are consistent with a contribution of potentially modifiable clinical factors to patients’ risk of developing PBP following breast-conserving surgery for breast cancer and suggest the need for further research specifically focused on these issues. 
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This project was completed as a part of the practicum component of the multidisciplinary Master of Public Health program through the University of Pittsburgh Graduate School of Public Health. I have also completed my M.B.B.S. (Bachelor of Medicine and Bachelor of Surgery), which included relevant medical education courses. My experiences, training, medical education, and my passion for public health led me to pursue this project. As an advocate of improving quality of life for individuals with chronic illnesses, I carried out the project described in this paper, under the supervision of Dana H. Bovbjerg PhD. 
In this project, we studied the development of chronic persistent breast pain in women who had undergone breast-conserving surgery as treatment for breast cancer. This project included primary data collection via medical records (e.g. EPIC, MARS and Powerchart) of various clinical factors that may increase the likelihood of development of chronic persistent breast pain. In addition, we examined demographic and medical variables from medical charts and self-reported questionnaires.






Development of persistent breast pain (PBP) in breast cancer survivors following surgical treatment of their cancer is thought to have a multifactorial etiology linked to various clinical factors (e.g. mode of anesthesia, and pre-existing mental disorders). Based upon a review of the literature, I hypothesize the following factors as likely to be related to the development of PBP in breast cancer survivors with a history of breast conserving surgical treatment: 
-	Survivors who experienced lymphedema post-surgery will be more likely to develop PBP. This hypothesis was highlighted in several metanalysis articles, including one that found participants with lymphedema were 2.58 times more likely to develop persistent breast pain  ADDIN EN.CITE (Leysen, Beckwee et al. 2017). The variable used to test this hypothesis in the present study was Lymphedema, a nominal categorical variable coded 1 if lymphedema was reported in the medical record  ADDIN EN.CITE (Leysen, Beckwee et al. 2017).
-	Survivors with lower education levels will be more likely to develop PBP. This hypothesis was highlighted in several metanalysis articles, including one that found that participants with lower levels of education (<12 or 13 years) had a higher chance (OR of 1.23) of developing chronic pain  ADDIN EN.CITE (Leysen, Beckwee et al. 2017). The variable used to test this hypothesis in the present study was Education, a dichotomous variable.
-	Survivors with a history of axillary lymph node dissection will be more likely to develop PBP. This hypothesis was highlighted in several metanalysis articles  ADDIN EN.CITE (Leysen, Beckwee et al. 2017). In one study, patients who underwent axillary lymph node dissection were 1.25 more likely to develop PBP. This was highlighted in Persistent post-mastectomy pain: Risk factors and current approaches to treatment (Bovbjerg, Keefe et al. 2019). The variable used to test this hypothesis in the present study was lymph node type axillary lymph node dissection (Ltype_ALND), a nominal categorical variable. Other forms of lymph node interventions were also examined, including axillary lymph node sampling (Ltype_ALNS) and sentinel lymph node biopsy (Ltype_SLNB).
-	Survivors with a history of hormone therapy treatment for their breast cancer will be more likely to develop PBP. This hypothesis was highlighted in several metanalysis articles, with one study indicating that survivors exposed to hormone therapy were 1.33 times more likely to experience PBP than those without a history of hormone therapy  ADDIN EN.CITE (Leysen, Beckwee et al. 2017). The variable used to test this hypothesis in the present study was “adjuvant hormone therapy” (AHrm), a nominal categorical variable.
-	Survivors with a history of radiation therapy treatment will be more likely to develop chronic persistent breast pain. This hypothesis was highlighted in several metanalysis studies, including one documenting that radiotherapy is a risk factor to develop PBP with an OR of 1.32  ADDIN EN.CITE (Leysen, Beckwee et al. 2017). The variable used to test this hypothesis in the present study was “adjuvant radiation” (Arad), a nominal categorical variable.
-	Survivors who are younger will be more likely to develop PBP. This hypothesis was highlighted in several prior studies. The variable used to test this hypothesis in the present study was “age”, a continuous variable  ADDIN EN.CITE (Leysen, Beckwee et al. 2017). 
-	Survivors with a history of mental health issues (e.g., depression, anxiety) will be more likely to develop PBP  ADDIN EN.CITE (Leysen, Beckwee et al. 2017). The variable used to test this hypothesis was a mental health diagnosis or treatment variable extracted from electronic health records (anxietyNew, depressionNew, otherNew), a nominal categorical variable.
-	Survivors with higher neutrophil to lymphocyte ratios (NLR) in their peripheral blood prior to surgery will be more likely to develop PBP. The variable used to test this hypothesis in the present study was the ANLR (absolute neutrophil lymphocyte ratio), a continuous variable  ADDIN EN.CITE (Bugada, Lavand'homme et al. 2016). This variable was calculated using absolute cell counts recorded from the medical record for the CBC with differential performed closest prior to the date of surgery.
2.0 	BackGROUND
Persistent breast pain (PBP) after breast cancer treatment is prevalent (with consensus estimates of approximately 30% of breast cancer survivors)  ADDIN EN.CITE (Leysen, Adriaenssens et al. 2019). According to the International Agency for Research on Cancer, breast cancer is the most common malignancy in the world  ADDIN EN.CITE (Leysen, Adriaenssens et al. 2019), The prevalence of persistent pain in this population is substantially higher than in other populations following other types of surgery. The development of PBP is thought to have a multifactorial etiology. Studies have linked patient-, treatment- and cancer-related risk factors (e.g. lymphedema, axillary lymph node dissection (ALND), chemotherapy, radiotherapy, hormone therapy and the use of pain medication, etc.). Other studies have linked the surgical procedure itself to the development of PBP  ADDIN EN.CITE (Leysen, Adriaenssens et al. 2019). 
Chronic or persistent pain is defined as pain lasting longer than normal healing time which often lacks the acute warning of physiological nociception. It is considered chronic when it persists for or relapses within 3-6 months and outlasts the normal healing phase. Breast cancer is the most common cancer in American women. With increased screening, early detection, and better treatment, the 5-year survival has increased over the past decade. A significant proportion of breast cancer survivors suffer from persistent pain, with prevalence ranging from 25%-60% across studies, and is recognized as a significant clinical problem. Suffering from persistent pain can be physically and emotionally debilitating, decreasing the quality of life in breast cancer survivors  ADDIN EN.CITE (Leysen, Adriaenssens et al. 2019).
3.0 	MATERIAL AND METHODS
3.1	Participants
The participants of the larger study from which data for the present study were drawn were women recruited between June 2009 to October 2012 from two different locations: Duke University Medical Center (DUMC) and the University of Pittsburgh Medical Center (UPMC).  The eligibility criteria consisted of the following: age 21 years and older, treated with breast conserving surgery, follow-up within 6-15 months post-treatment, and diagnosis of breast cancer stage I-IIIA. At the time of diagnosis, 61.9% of the participants had Stage I breast cancer, 25.7% Stage II, and 11.8% Stage III breast cancer. The sample consisted mostly of white women mean age of 59 years.
A total of 526 breast cancer survivors provided written informed consent. The participation rate was 83.4%. Out of the consented breast cancer survivors, a previous report focused on psychological responses to PBP included 417 survivors (1 withdrew, 83 were excluded, and 25 did not complete breast pain questions) (Bovbjerg, Keefe et al. 2019). The final sample included in this new analysis was 371 due to further exclusions (9 individuals who had previous extensive breast surgery including reconstruction, reduction, or implants and 12 participants who underwent bilateral breast surgery). The participants were further excluded from the new data set if they met any of the following criteria:
A)	Endorsed pain “most of my life” on BPQ_4a variable (duration of breast pain) or were missing data for this item
B)	Had surgery less than 6 months ago
C)	Missing data for all of the following variables 
- BPQ_1a (breast pain intensity right now)
- BPQ_2a (worst breast pain intensity in the past month)
- BPQ_3a (average breast pain intensity in the past month)
Cancer survivor participants were further grouped into persistent pain group and non-persistent pain group based on the following criteria:
	Participants who answered ‘I do not have breast pain’ or had breast pain ‘less than 6 months’ on BPQ_4a were grouped in the no persistent breast pain group. (CpainNew variable=0)
	Participants who had bpainintensity=0 and answered ‘between 6 and 12 months’ or ‘more than 1 year’ on BPQ_4a were grouped in the no persistent breast pain group. (CpainNew variable=0)
	Participants who answered ‘between 6 and 12 months’ or ‘more than 1 year’ on BPQ_4a were grouped in the persistent breast pain group if they had bpainintensity > 0 (mean of BPQ_1a, BPQ_2a, BPQ_3a). (CpainNew variable=1)
To further investigate the influence of when persistent pain developed on the relationships with clinical predictors, we constructed the following variable CPainNew2. For this variable (CPainNew2), a separate category was created for those individuals reporting pain longer than one year but the time since surgery was less than one year. Another category was created for those who reported pain for six months to a year, whose surgery was more than a year previous. The new variable was coded as follows:
	CPainNew2=0 no persistent breast pain if bpainseverity=0 or duration < 6 months
	CPainNew2=1 persistent breast pain that started after surgery
	CPainNew2=2 persistent breast pain that started prior to surgery
	CpainNew2=3 persistent breast pain that started at least six months after surgery 
3.2	Procedures
For the original study, patient medical records were reviewed under a HIPAA waiver, to assess eligibility (mammography clinic schedules and patient medical records). Potential participants were contacted by the breast image clinic, they were sent a letter introducing the study along with contact information for research staff so patients could contact them if they had any questions regarding the study prior to their appointment or if they had no intention to participate so they would not be approached. Women were approached about the study upon completion of registration paperwork at the breast imaging clinics and informed consent procedures were performed in a private area. Self-reported demographic information was collected at the participants convenience during the appointment. The variables collected were age, BMI, marital status, single, married, level of education received, race, menstrual status, smoking history and mental history. Using Cerner Powerchart, Epic, and MARS, relevant medical history was extracted including the following: We collected the following medical variables neoadjuvant therapy (chemotherapy, radiation therapy, and hormonal therapy), adjuvant therapy (chemotherapy, radiation therapy, brachytherapy, hormonal therapy, biologic therapy), lymph node assessment (sentinel node biopsy, axillary node dissection, and axillary node sampling) and moths post-surgery.  In a subset of participants (UPMC site) the following additional variables were examined: Type of surgery (same day vs. inpatient), medications administered (inpatient and outpatient), anesthesia medications administered, and CBC values (neutrophil to lymphocyte ratios).
3.2.1	Self-report questionnaires 
The self-reported questionnaires explored of the following factors and variables:
A)	Breast-pain: This section consisted of three items adapted from the Brief Pain Inventory (BPI) (Cleeland et al. 1994). The Brief Pain inventory was used because it demonstrated sensitivity and consistency in prior studies. We looked at the average worst breast pain intensity, average breast pain intensity during the past month, and breast pain intensity right now in order to increase the dependability and responsivity. The items used a scoring metric which consisted of 0 (equivalent to no pain) to 10 (the worst debilitating pain). A separate item assessed breast pain duration: ‘How long have you had breast pain?’, which had the following options: ‘less than 6 months’, ‘6 to 12 months’, ‘more than 1 year’, and ‘most of my life.’ We defined persistent breast pain as breast pain with a minimal duration of 6 months. Consistent with prior studies, we used a composite pain score of three or higher to determine clinically significant pain levels. 
B)	Breast-pain related variables: Other factors assessed included pain unpleasantness, pain frequency, interference, and medication use for breast pain. In order to assess pain unpleasantness, we used a visual analogue scale (100mm line anchored by ‘not bad at all’ and ‘most intense unpleasantness imaginable’). The frequency of pain was reported as the following: never, less than monthly, every month, every week, every day, or every hour. A new variable was created (newpainfreq) which grouped the participants indicating experiencing pain every day or every hour into one. We computed a new variable using the body map locations marked to indicate pain (excluding the breasts) (bodyNO). 
Assessment of pain interference was done by incorporating two elements from the BPI: a) how much breast pain interfered with daily activities and b) how much pain interfered with sexual activities/intimacy in the past month. These elements were scored on a scale ranging from 0 (‘no interference’) to 10 (‘extreme interference’). The average of these two elements contributed to the pain interference score. Lastly medication history was reported in relation to how often participants ingested medications to relieve breast pain. This was coded as never, less than monthly, every month, or daily. A new variable was created (bpainmed3cat) which grouped the participants indicating medication use less than monthly and every month into one.
3.2.2	Medical chart Review
Relevant data was extracted for a subset of participants from the UPMC site by conducting an in-depth medical chart review using the following electronic medical records systems: Cerner Powerchart, MARS and EPIC. The following clinical variables were extracted:
	Medication usage: Discharge summaries given at the time of discharge post-surgery were used. Our main focus was to record any pain medication usage. We extracted the information regarding which pain medications were recommended/prescribed and if the participant was on any other medications at that time. These variables were further subdivided into pain medication usage (opioids and over the counter pain medicines (Tylenol, aspirin, etc.)) and miscellaneous medications. We constructed new variables for the pain medications subset (Dopioid and dOTC). The Dopioid variable indicated which participants received prescriptions for opioid medication at the time of discharge: Dopioid=1 if they received opioids and Dopioid=0 if they did not receive opioids. The dOTC variable indicated which participants were advised to take over the counter pain medications at the time of discharge: dOTC=1 if they were advised to take over the counter pain medications at time of discharge and dOTC=0 if they were not advised to take over the counter pain medications at the time of discharge. Some participants were advised to use a combination of opioids and over the counter pain relievers (Dopioid=1 & dOTC=1).
	Duration of surgery/hospital stay: Based on the discharge summary and operative reports, we assessed whether the patient received inpatient services (required hospital stay post-surgery) or outpatient services (same day surgery and discharge). We created a variable (sameday) to examine whether same day surgery increased the likelihood of developing PBP. The variable was coded accordingly: sameday=1 if the patient was discharged the same day as the breast surgery and sameday=0 if the patient required hospital stay post-surgery. 
	Past medical history: Comorbidities were assessed from the discharge summaries. A variable (comorbidity) was created and coded accordingly: If the patient had any chronic medical conditions or was taking long-standing medications then comorbidity=1 and if the patient did not have any chronic medical conditions and was not talking any long-standing medications then comorbidity=0.
	Anesthetic history: We used the anesthesia record to extract the mode of anesthesia, anesthetic medications administered during the surgery, and the dosage. Multiple variables were created from the anesthetic data available, but unfortunately due to uniformity among participants only a few of these variables were analyzed. The following variables were assessed:
	Type of anesthesia: we assessed the mode of anesthesia by computing the variable typeofanesthesia. This variable was coded accordingly: if individuals received local anesthesia typeofanesthesia=1, if individuals received general anesthesia typeofanesthesia=0, and if anesthesia history was unknown or missing typeofanesthesia=9.
	The administration of the following anesthetic medications was recorded, and variables were created for each. 
o	Administration of Fentanyl. If Fentanyl was administered, then the variable fentanyl=1, and if Fentanyl was not administered then the variable fentanyl=0.
o	Administration of Midazolam. If Midazolam was administered, then the variable midazolam=1 and if Midazolam was not administered then the variable midazolam=0.
o	Administration of Propofol. If Propofol was administered, then the variable propofol=1 and if Propofol was not administered then the variable propofol=0.
o	Administration of Succinylcholine. If Succinylcholine was administered, then the variable succinylcholine=1 and if Succinylcholine was not administered then the variable succinylcholine=0.
The following figure shows how the data was collected for the previously listed variables, including the number of each type of record available and an explanation of the missing data. These numbers were generated prior to applying any exclusion criteria to the UPMC sample.

Figure 1 UPMC Site Sample Collection Flow Diagram
4.0 	StATISTICAL ANALYSES
Analyses were conducted using SPSS statistical software version 25 (IBM, Armonk, NY, USA). We ran descriptive statistics, conducted bivariate analyses (e.g chi-square for categorical variables and independent t-test for continuous variables) in order to determine whether breast cancer survivors who underwent breast-conserving surgery and developed PBP differed from those who did not develop PBP (p<0.05) with regard to psychosocial, demographic, or clinical variables. In Phase I, two groups were compared, those with persistent breast pain (PBP+ group) and those without persistent breast pain (PBP- group) using the CpainNew variable. In Phase II, the PBP+ group was further subdivided into the following categories: CPainNew2=0 no persistent breast pain if bpainseverity=0 or duration < 6 months
	CPainNew2=1 persistent breast pain that started after surgery
	CPainNew2=2 persistent breast pain that started prior to surgery
	CpainNew2=3 persistent breast pain that started at least six months after surgery 
We analyzed demographic and clinical variables to examine whether group differences existed. The demographic variables we examined were: age, BMI, education, race, marital status, menopausal status, smoking status and mental health (e.g. Depression, anxiety). The clinical variables examined were the following: neoadjuvant therapy (e.g. neoadjuvant chemotherapy, neoadjuvant radiation therapy, neoadjuvant hormonal therapy), adjuvant therapy (e.g. radiation therapy, brachytherapy, hormonal therapy, chemotherapy, adjuvant biologic therapy), lymph node assessment, sentinel lymph node biopsy, axillary lymph node sampling, axillary lymph node dissection, lymphedema and months post-surgery.
5.0 	RESULTS
5.1	Phase 
In phase , the two-group approach was utilized. The grouping variable used was CpainNew which was coded accordingly: Participants who answered I do not have breast pain or had breast pain less than 6 months on BPQ_4a were grouped in the non-persistent pain group. (CpainNew variable=0) along with participants who had bpainintensity=0 and answered between 6 and 12 months, more than 1 year, or most of my life on BPQ_4a were grouped in the non-persistent pain group. (CpainNew variable=0). The participants who answered between 6 and 12 months, more than 1 year, on BPQ_4a were grouped in the persistent pain group if they had bpainintensity > 0 (mean of BPQ_1-3). (CpainNew variable=1).
In this phase we examined demographic variables, clinical variables, and ran descriptive analysis for the persistent breast pain category.
5.1.1	Comparison of demographic characteristics using CpainNew variable
Table 1. Summarizes and compares demographic characteristics for the two groups. The demographic characteristics were analyzed using chi-squared tests and t-tests, with the CpainNew variables. They did not reveal any significant differences between the PBP+ group and PBP- group. The sample consisted of far more white women then non-white women, making possible differences hard to assess. For the other variables analyzed most seemed to be evenly distributed between the PBP+ group and PBP- group. 
Table 1 CpainNew Demographic Characteristics
	PBP+Cancer survivor group(n=180)	PBP-Cancer survivor group(n=191)	Statistical Results	Statistical Results	Statistical results








Smoking StatusCurrent smokeEver smoke*Nicotine use in last 24hrs	14.447.86.7	8.940.36.3	.102.172.866	111	2.670a1.866a.029a
Mental HealthDepressionAnxietyOther	24.416.73.3	19.920.41.6	.206.207.332	222	3.158a3.154a2.202a
*The ever smoke group includes the individuals who currently smoke
5.1.2	Comparison of computed clinical variables using CpainNew variable
Table 2 summarizes and compares clinical variables we computed. The computed clinical variables combine multiple subcategories in order to create a broader category. The following variables were created: 
	All lymph node interventions: We created a variable for axillary lymph node intervention including both sampling and dissection (ALNint): computed if variables LType_ALNS=1 (axillary lymph node sampling) or LType_ALND=1 (axillary lymph node dissection), then ALNint=1. If this criterion was not met, then ALNint=0.
	History of mental health: If there was a history of a mental health issue reported in the medical chart, we created a variable to depict it (MHhist). MHhist=1 if anxiety (AnxYN=1), depression (DepYN=1), or if any other mental illness was listed (OthYN=1). If this criterion was not met, then OthYN=0
	Neoadjuvant therapy: We created a variable to indicate whether the participant received any form of neoadjuvant therapy (neoADJ). neoADJ=1 if Neochem=1 or NeoRad=1 or NeoHrm=1 or NeoBio=1. If this criterion was not met, then neoADJ=0.
	Adjuvant therapy: We created a variable to indicate whether the participant received any form of adjuvant therapy (ADJ). ADJ=1 if AdjChem=1 or AdjRad=1 or AdjBrach=1 or AdjHrm=1 or AdjBio=1. If this criterion was not met, then ADJ=0.
	Complications: We created a variable to indicate whether the participant had any post-surgical complications (compYN). compYN=1 if any post-surgical complications were present in the month following surgery, or if lymphedema=1 and compYN=0 if no post-surgical complications were present.
The two PBP groups significantly (p<.05) differed in lymphedema and post-surgical complications upon Chi-square analysis.
Table 2 CpainNew Computed Clinical Variables
	PBP+ Cancer survivor group(n=180)	PBP- Cancer survivor group(n=191)	Statistical Results	Statistical Results	Statistical Results
	%	%	 CHI-Sq Sig.(2-sided)	df	value
Neoadjuvant therapy	           17.8	18.3	.891	1	.019a
Adjuvant therapy	99.4	98.4	.344	1	.895a
Lymphedema	38.3	27.7	.018	1	5.637a
All lymph node interventions	24.4	21.9	.575	1	.314a
Mental History	29.4	31.9	.603	1	.271a
Complications	55.0	38.3	.018	1	5.637a
5.1.3	Comparison of clinical characteristics using CpainNew variable
Table 3 summarizes and compares clinical variables. The following treatment variables were examined between the PBP+ group and PBP- groups. Chi-square analysis revealed significant differences (p<.05) between the PBP+ group and PBP- group related to sentinel lymph node biopsy and independent T-tests revealed a significant difference (p<.05) in months post-surgery between the groups.
Table 3 CpainNew Clinical Characteristics
	PBP+ Cancer survivor group(n=180)	PBP- Cancer survivor group(n=191)	Statistical Results	Statistical results	Statistical results 
	%	%	CHI-Sq.Sig  (2-sided)	df	value
Neoadjuvant therapyChemotherapyRadiation therapyHormonal therapy	16.70.61.7	16.81.00.5	.982.597.287	111	.001a.279a1.135a






Sentinel lymph node biopsy	96.7	89.6	.007	1	7.245a
Axillary lymph node sampling	11.1	9.4	.592	1	.287a
Axillary lymph node dissection	16.7	17.3	.876	1	.025a
	M(SD)	M(SD)	Sig (2-tailed)	df	t
Months post-surgery	11.0	10.4	.018	369	2.382
5.1.4	Persistent breast pain-related variables using CpainNew variable
Table 4 compares PBP-related variables in the two groups. Group comparisons found that pain intensity differed between PBP+ group (M=2.4, SD=1.5) and PBP- group (M=0.9, SD=1.5). Pain unpleasantness differed between PBP+ group (M=22.8, SD=18.7) and PBP- group (M=8.9, SD=17.2). There was similar pattern of differences shown across the other pain-related variables.
Table 4 CpainNew Pain related Variables 
	PBP +Cancer survivor group(n=180)	PBP -Cancer survivor group(n=191)	Statistical Results	Statistical Results	Statistical results
	M(SD)	M(SD)	Sig (2-tailed)	df	t
BPI breast pain intensity score (0-10 scale)	2.4 (1.7)	0.9 (1.5)	.000	369	8.726
Pain unpleasantness (0-100)	22.8 (18.9)	8.9 (17.2)	.000	342	7.154
Body pain locations (excluding the breast)	2.8 (3.2)	1.9(2.7)	.004	369	2.870
	%	%	CHI-Sq. Sig (2-sided)	df	Value 
Breast pain frequencyDo not have painLess than monthlyMonthlyWeeklyDaily	030.519.425.023.3	58.118.35.27.39.4	.000	4	155.031a
Use medication to relieve breast painNeverOnce per month or lessDaily	79.411.76.1	89.57.32.1	.036	2	6.635a
Pain interferes with activities (% yes)	35.6	19.9	.001	1	11.002a
5.1.5	Comparison of clinical characteristics in UPMC site sample using CpainNew variable
Table 5 summarizes and compares the clinical variables in a subset of participants (participants from UPMC site) for CpainNew. A limitation in data collection was that certain records were unavailable, leading to different number of participants in each variable. The percentages for the table below were computed from the total number available in each category. For some variables assessed, the sample size was not large enough to allow appropriate statistical evaluation, so comparisons were not made.
Table 5 CpainNew Clinical Characteristics in UPMC site sample




Mode of AnesthesiaGeneralLocal 	76.47.1	88.45.4	2	.706	.697a
Drugs administered during anesthesia FentanylMidazolamPropofolSuccinylcholine	27.927.927.98.5	26.826.834.88.9	2222	.397.397.507.491	1.849a1.849a1.359a1.422a
Sameday	52.6	45.7	1	.052	3.775a
Comorbidities	30.7	42.0	1	.447	.578a
Pain medication usageOver the counter pain medicineOpioid usage 	21.432.1	26.833.0	11	.657.255	.197a1.298a
5.2	Phase 
5.2.1	Comparison of Demographic characteristics using CpainNew2 variable
Table 6. Summarizes and compares demographic for the two groups in CpainNew2. The following demographic variables were examined between the PBP+ cancer survivor group, which was subdivided into 3 categories based on the timing of the start of persistent pain, PBP+ Cancer survivor group persistent breast pain that started after surgery, PBP+ Cancer survivor group persistent breast pain that started prior to surgery, PBP+ Cancer survivor group persistent breast pain that started at least six months after surgery, and PBP- cancer survivor group. The analysis did not reveal any significant results.
Table 6 CpainNew2 Demographic characteristics
	PBP+ Cancer survivor group persistent breast pain that started after surgery(n=137)	PBP+ Cancer survivor group persistent breast pain that started prior to surgery(n=20)	PBP+ Cancer survivor group persistent breast pain that started at least six months after surgery (n=23)	PBP- Cancer survivor group(n=191)	Statistical Results	Statistical results	Statistical results 





Educationvocational training or less educationcollege degree or more education	51.846.0	25.075.0	47.852.2	50.348.2	.133	3	5.603a
Racenon-whitewhite	0.799.3	5.095.0	0100	1.697.9	    .426	3	2.783a
Post-Menopausal	82.5	75.0	78.2	84.4	.458	3	2.600a
Smoking StatusEver smoke*Current smokeNicotine use in last 24hrs	48.913.98.0	30.010.05.0	56.521.70	40.38.96.3	.154.210.519	311	5.255a4.126a2.264a
Mental HealthDepressionAnxietyOther	24.1   15.32.9	65.020.075.0	52.221.74.3	19.920.41.6	.374.629.732	666	6.459a4.354a3.592a
5.2.2	Comparison of computed clinical characteristics using CpainNew2 variable
Table 7. summarizes and compares clinical variables computed for the groups in CpainNew2. We later computed clinical variables from combining multiple subcategories in order to create a broad category which was previously described. The categories computed were neoadjuvant therapy, adjuvant therapy, lymphedema, all lymph node interventions and mental history. Chi-square analysis yielded significant difference (p<.05) among PBP+ group and PBP- group in who received neoadjuvant therapy and received any lymph node interventions.
Table 7 CpainNew2 Computed Clinical Variables




Lymphedema	        10.9	         12.2	         21.7	7.8	.031	3	8.910a
All lymph node interventions	        39.4	         19.5	         30.4	27.6	.096	3	6.338a
Mental History	         29.4	        31.9	        39.1	31.7	.603	3	1.475a

5.2.3	Comparison of clinical characteristics using CpainNew2 variable
Table 8. summarizes and compares clinical variables for the groups in CpainNew2. The following demographic variables were examined between the PBP+ cancer survivor group (which was subdivided into 3 categories based on the duration of pain) and PBP- cancer survivor group. Chi-square analysis yielded significant difference (p<.05) among PBP+ group and PBP- group in who received chemotherapy, underwent sentinel lymph node biopsy, and the months post-surgery.
Table 8 CpainNew2 Clinical Characteristics
	PBP+ Cancer survivor group persistent breast pain that started after surgery(n=137)	PBP+ Cancer survivor group persistent breast pain that started prior to surgery(n=20)	PBP+ Cancer survivor group persistent breast pain that started at least six months after surgery(n=23)	PBP- Cancer survivor group(n=191)	Statistical Results	Statistical Results	Statistical Results
	%	%	%	%	p-value	df	value








Axillary lymph node sampling	9.5	20.0	13.0	9.4	.477	3	2.491a




5.2.4	Comparison of clinical characteristics in UPMC site using for CpainNew2 variable
For a subset of participants (UPMC location) we analyzed additional variables which were extracted from electronic medical records. We looked at the following clinical and treatment variables: A limitation in data collection was that certain records were unavailable, leading to different number of n in each variable. The ratios for the table below were computed from the total number available in each category. The sample size was not large enough to show statistically significant results (p<.05) and would require further analysis.

Table 9 CpainNew2 Clinical Characteristics in  UPMC site sample




Mode of AnesthesiaGeneralLocal 	76.47.1	88.45.4	2	.706	.697a
Drugs administered during anesthesia FentanylMidazolamPropofolSuccinylcholine	27.927.927.98.5	26.826.834.88.9	2222	.397.397.507.491	1.849a1.849a1.359a1.422a
Sameday	52.6	45.7	1	.052	3.775a
Comorbidities	30.7	42.0	1	.447	.578a
Pain medication usageOver the counter pain medicineOpioid usage 	21.432.1	26.833.0	11	.657.255	.197a1.298a

6.0 	Discussion
In this study we examined demographic factors (like age, marital status, BMI, and social history) and clinical variables (treatment, type of biopsy) as possible predictors of the development of persistent breast pain (PBP) following surgery for breast cancer. We constructed variants of medical variables from data we had extracted. Prevalence of PBP in women who underwent breast-conserving surgeries was 48.5%. We compared the PBP+ group with the PBP- group using CpainNew and CpainNew2 variables. For all our analysis we excluded participants complaining of pain all their lives in order to better define PBP. Persistent breast pain is defined as continued pain at or surrounding the surgical site lasting 6 months or longer (Bovbjerg, Keefe et al. 2019).
In phase  we used the two-group approach (CpainNew) with a larger sample size. In this phase we found that women who developed PBP were more likely to have undergone, any lymph node intervention including sentinel lymph node biopsy and chemotherapy. There was also a linkage between the number of months post-surgery and post-surgical complications (including lymphedema) with the development of PBP. In a subgroup of individuals (participants from the UPMC site) further analysis was conducted using variables such as: mode of anesthesia, use of pain medications (opioids vs. OTC), comorbidities, duration of hospital stay (same day/outpatient vs. inpatient). Since there were published studies showing that increased preoperative levels of NLR predicted higher post-surgical pain in patients who underwent inguinal surgery  ADDIN EN.CITE (Bugada, Lavand'homme et al. 2016), we also looked at absolute neutrophil monocyte ratios (NMR) and absolute neutrophil lymphocyte ratios (NLR), but found no differences between our PBP groups with regard to those variables. 
In phase  we used the two-group approach, but further divided the PBP+ group into three subgroups based on the duration of pain (CpainNew2). In this phase we found that women who developed PBP were more likely to have undergone a lymph node intervention including sentinel lymph node biopsy or neoadjuvant therapy. There was also a linkage between the number of months post-surgery and post-surgical complications including lymphedema with the development of PBP. In a subgroup of individuals (participants from the UPMC site) further analysis was conducted using variables such as: mode of anesthesia, use of pain medications (opioids vs. OTC), comorbidities, and duration of hospital stay (same day/outpatient vs. inpatient). We also looked at absolute neutrophil and absolute monocyte ratios, which did not show any differences between groups. This may have been due to the time variation of when complete blood count (CBC) panels were done and due to the small sample size (UPMC site).
Meta-analysis had previously examined seventy risk factors examined for development of persistent pain in breast cancer survivors. One variable looked at was lymph node dissection, axillary versus sentinel lymph node. Women who underwent axillary lymph node dissection were 1.25 times more likely to develop PBP compared then those who underwent sentinel lymph node dissection  ADDIN EN.CITE (Leysen, Beckwee et al. 2017). When we looked at these variables, we found no difference in axillary lymph node dissection between the PBP+ group and the PBP- group, but we did see a difference between groups in relation to sentinel lymph node biopsy. The chemotherapy variable showed differences between PBP groups. Prior studies suggested that women were 1.44 times more likely to develop PBP if they underwent chemotherapy versus if they did not  ADDIN EN.CITE (Leysen, Beckwee et al. 2017). In our Phase  analysis using the CpainNew variable we saw a difference between PBP groups in participants who received chemotherapy versus those who did not. Prior literature indicates that women who received chemotherapy were 1.44 times more likely to develop PBP  ADDIN EN.CITE (Leysen, Beckwee et al. 2017).
Lymphedema was studied in three prior articles and found to have odds of developing persistent pain that were 2.58 times higher in the individuals who developed lymphedema post-surgery. Results from various studies showed that a reduction of lymphedema was correlated with a decrease in pain  ADDIN EN.CITE (Leysen, Beckwee et al. 2017). Our study yielded similar results in terms of showing lymphedema increased the likelihood of developing PBP. One particular variable, which has not been mentioned in the literature (to our knowledge), is the development of complications post-surgery as a contributing factor in increased likelihood of developing PBP. In our study we examined a broad scope of complications to see whether post-operative complications in general increased the likelihood of development of PBP. We looked at whether there were post-surgical complications during an ER visit post-surgery, infection, home care, complications limiting regular activities, lymphedema occurrence and if there were complications of additional surgery (not including re-excision and lymph node assessment).
Neoadjuvant therapy was another variable found to be predictive of PBP in the present study, which was not mentioned in the previous literature (to our knowledge). The neoadjuvant therapy variable in the present study showed a significant difference between the preoperative start subgroup of the PBP+ pain group and the PBP- group in phase  (CpainNew2). This variable looked at all types of neoadjuvant therapy (radiation, chemotherapy, hormonal) and if they received any form of neoadjuvant chemotherapy this variable was coded as positive.
Some limitations of this study must be mentioned. Among these limitations were that some of the medical chart variables for the UPMC sample were not fully accessible, leaving us to have an extremely small sample size. In the larger sample we had a limitation of which variables we could use for our analysis. In the future it would be beneficial to explore linear correlations between the statistically significant groups and run additional analyses including the medical variables for the UPMC site, in a larger sample (e.g., Duke and UPMC sites combined).
	In summary, the findings from the present study are consistent with a contribution of potentially modifiable clinical factors to patients’ risk of developing PBP following breast-conserving surgery for breast cancer and suggest the need for further research specifically focused on these issues. 
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